December 2012

Global Markets for Hyaluronic Acid Viscosupplementation 2013

Introduction:

The global market for HA viscosupplementation will exhibit strong single-digit growth over the forecast period, driven by favorable demographic trends and the adoption of new products.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the HA viscosupplementation market in the US, Europe (France, Germany, Italy, Spain, UK), and Asia Pacific and Brazil (Australia, Brazil, China [Mainland China and Hong Kong], India, Japan, South Korea, Taiwan), with market projections 5 years into the future.

We have up-to-date reports on a wide range of medical device markets worldwide.

Questions Answered in This Report:

  *   The global market for HA viscosupplementation will exhibit strong growth over the forecast period, in spite of unfavorable economic conditions in some regions.

Which regions are contributing most to this growth?

What demographic trends are impacting this growth?

  *   The introduction of the 1-injection HA viscosupplementation into more markets will alter the market landscape.

What are the advantages of the 1-injection treatments over 3- or 5-injection treatments?

Which regions are adopting the 1-injection products the most quickly?

To what extent will the trend toward 1-injection treatments impact the 3- and 5-injection segments?

  *   While large companies hold the dominant market shares in the global HA viscosupplementation market, smaller competitors have also managed to carve out a niche in this space.

Which companies hold the highest market shares, and in what regions?

In what regions do local competitors fare best and what are their strategies for success?

Scope:

Geographies Covered:

Region

US

Europe

Country

France

Germany

Italy

Spain

UK

Asia Pacific and Brazil

Country

Australia

Brazil

China

Region

Mainland China

Hong Kong

India

Japan

South Korea

Taiwan

Procedures Covered: Our analysis uses the following breakdown of procedures:

Product Type

HA Viscosupplementation

Anatomy

Knee

Shoulder

Hip

Other*

Number of Injections

1

3

5

* Other includes the digits, elbow, and ankle.

Products Covered: Our analysis uses the following breakdown of products in the market:

Product Type

HA Viscosupplementation

Number of Injections

1

3

5

Market Forecast Features: Based on primary research with industry professionals, we use our proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, unit sales, ASPs, and market values over a 7-year period (2011–2017).

Competitive Analysis: We provide a detailed analysis of the competitive landscape and market shares for leading competitors.

Authors:

Brady Baker
Kyle Verleyen
Kristina Vidug

Contributors
Omnya Elmassad
Karen Gierszewski
Lynn Gierszewski
Samuli Heilala, M.Sc.
Nancy Huynh
Veronica Ross



Search Reports

CONTACT US
Email Opt-in: I consent to receive e-mails from DRG regarding healthcare market information, product announcements, promotions, webinar and seminar invitations and other messages. I understand that I may withdraw my consent and unsubscribe or update my email preferences at any time. Please read our Terms of Use and Privacy Policy and contact us with any questions.

Mentioned in this report:

  • Anika Therapeutics
  • Associated Medical Supplies
  • Bharat Biotech
  • Bioniche Pharma
  • Bioventus
  • Cadila Pharmaceuticals
  • Chi Fu Trading
  • Chugai Pharmaceutical
  • Croma-Pharma
  • curasan
  • DePuy
  • DJO Global
  • Documedica
  • Dongkwang Pharm
  • EMS Sigma Pharma
  • Ferring Pharmaceuticals
  • Fidia Farmaceutici
  • Fuji Pharma
  • Galderma
  • Genzyme
  • Goodman
  • Hangzhou Gallop Biological Products
  • Harvester Trading
  • Hisamitsu Pharmaceutical
  • Huons
  • Kaken Pharmaceutical
  • Kunming Baker Norton Pharmaceutical
  • Laboratoires Genévrier
  • Laboratoires Pierre Fabre
  • LCA Pharmaceutical
  • LG Life Sciences
  • Lifecore Biomedical
  • Lupin Pharmaceuticals
  • Maruho
  • Med Pharma
  • Meiji Seika Pharma
  • Merck
  • Mylan
  • Nichi-Iko Pharmaceutical
  • Nippon Zoki Pharmaceutical
  • Nipro
  • Nissin Pharmaceutical
  • PCE
  • PDI
  • Piramal Enterprises
  • Q-Med
  • Qufu Haitao International Trading
  • Recordati
  • Rottapharm Madaus
  • Sanofi
  • Sawi Pharmaceutical
  • Sci Vision Biotech
  • Seikagaku
  • Shandong Bausch & Lomb Freda Pharmaceutical
  • Shanghai Baijiayi Pharmaceutical
  • Shanghai Haohai Bio-Tech
  • Shin Poong Pharmaceutical
  • Shiono Chemical
  • Smith & Nephew
  • Taiyo Yakuhin
  • Takata Seiyaku
  • Tedec-Meiji Farma
  • Towa Pharmaceutical
  • TRB Chemedica
  • Tsuruhara Pharmaceutical
  • Uji Pharmaceutical
  • Unimed Pharm
  • Virchow Biotech
  • Yoo Young Pharm
  • Zimmer
Decision Resources Group brands include: